PMID- 29440147
OWN - NLM
STAT- MEDLINE
DCOM- 20190520
LR  - 20211108
IS  - 1538-7445 (Electronic)
IS  - 0008-5472 (Linking)
VI  - 78
IP  - 6
DP  - 2018 Mar 15
TI  - The Balance Players of the Adaptive Immune System.
PG  - 1379-1382
LID - 10.1158/0008-5472.CAN-17-3607 [doi]
AB  - Equilibrium between immune activation and suppression may be necessary to 
      maintain immune homeostasis, because proinflammatory effector T cells (defined as 
      antiregulatory T cells) counteract the functions of regulatory immune cells. 
      These self-reactive T cells recognize human leukocyte antigen (HLA)-restricted 
      epitopes derived from proteins expressed by regulatory immune cells such as IDO, 
      PD-L1, PD-L2, or arginase. The activation of such proinflammatory effector T 
      cells offers a novel way to directly target the tumor microenvironment, 
      potentially giving them considerable clinical value, especially in patients with 
      cancer. Vaccination against genetically stable cells with regular HLA expression 
      is an attractive way to directly target immunosuppressive cells in addition to 
      attracting proinflammatory cells into the tumor microenvironment. Importantly, 
      vaccination toward IDO or PD-L1 to potentiate such T cells have proven safe, with 
      minimal toxicity in the clinical phase I trials conducted thus far.Cancer Res; 
      78(6); 1379-82. (c)2018 AACR.
CI  - (c)2018 American Association for Cancer Research.
FAU - Andersen, Mads Hald
AU  - Andersen MH
AD  - Center for Cancer Immune Therapy (CCIT), Department of Hematology, Copenhagen 
      University Hospital, Herlev, Denmark. mads.hald.andersen@regionh.dk.
AD  - Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, 
      Denmark.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20180213
PL  - United States
TA  - Cancer Res
JT  - Cancer research
JID - 2984705R
RN  - 0 (B7-H1 Antigen)
RN  - 0 (CD274 protein, human)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Epitopes)
RN  - 0 (IDO1 protein, human)
RN  - 0 (Indoleamine-Pyrrole 2,3,-Dioxygenase)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - B7-H1 Antigen/immunology/metabolism
MH  - Cancer Vaccines/*pharmacology
MH  - Epitopes/immunology
MH  - Humans
MH  - Immunotherapy/methods
MH  - Indoleamine-Pyrrole 2,3,-Dioxygenase/immunology/metabolism
MH  - Interferon-gamma/immunology/metabolism
MH  - Neoplasms/*immunology/pathology/therapy
MH  - T-Lymphocytes/*immunology
MH  - T-Lymphocytes, Regulatory/immunology
MH  - Tumor Microenvironment/*immunology
EDAT- 2018/02/15 06:00
MHDA- 2019/05/21 06:00
CRDT- 2018/02/15 06:00
PHST- 2017/11/20 00:00 [received]
PHST- 2017/12/12 00:00 [revised]
PHST- 2018/01/02 00:00 [accepted]
PHST- 2018/02/15 06:00 [pubmed]
PHST- 2019/05/21 06:00 [medline]
PHST- 2018/02/15 06:00 [entrez]
AID - 0008-5472.CAN-17-3607 [pii]
AID - 10.1158/0008-5472.CAN-17-3607 [doi]
PST - ppublish
SO  - Cancer Res. 2018 Mar 15;78(6):1379-1382. doi: 10.1158/0008-5472.CAN-17-3607. Epub 
      2018 Feb 13.